| Objective: Non–Hodgkin'lymphoma (NHL) represent a heterogeneous group of disease whose prognosis is difficult to predict, and so it is important to monitor disease activity, evaluate effectiveness of treatment and predict prognosis. Recently, Many studies showed that adhesion moleculars (AM) are closely associated with the occurrence and progress of tumor. In search of biochemical markers useful for monitoring of NHL patients, adhesion molecules attracted attention, and particular attention has been paid to ICAM-1. ICAM-1, a 90KD member of the immunoglobulin superfamily, is the ligend for the integrin lymphocyte function associated antigen–1(LFA–1). ICAM-1/LFA-1 molecules are widely distributed among haemopoietic and non-haemopoietic cells, and they regulate important cell-cell and cell-stromal interactions. Recently, an 82KD soluble form of ICAM–1(sICAM–1) was detected in serum of normal subjects as well as in patients with inflammatory conditions, and elevated levels of sICAM–1 were reported in malignant disease such as malignant melanoma, acute lymphoblastic leukaemia (ALL), Hodgkin's disease and NHL. In this study, we detected plasma sICAM–1 levels of NHL patients before and after treatment by ELISA, and followed up the relapse and survival status of NHL patients who have received 8~9 cycles of chemotherapy. We analysed the correlation of plasma levels of sICAM–1 with the clinicopathological characters, the short-term treatment outcome and the several markers associated with prognosis, in order to clarify its significance in clinical situation, treatment outcome and prognosis of NHL patients. Methods: We analyzed plasma levels of sICAM–1 in a series of 43 newly diagnosed NHL patients from the department of Hematology in the Forth Affiliated Hospital, He Bei university of Medical Sciences and 20 normal controls. Moreover, when the 26 patients choosed randomly from the above 43 patients were in complete remission, partial remission after 1 cycle chemotherapy and relapse of the disease, plasma levels of sICAM–1 were measured. sICAM–1 levels were quantified by an Elisa assay. Median age was 50 years; 26 were male; 27 presented with advanced clinical stage (III/IV), 20 with B symptoms, 17 with bone marrow infiltration, and 26 with originally extranodal sites, Most patients received ITOP regimen. The results were expressed in ng/ml. All statistical analysis were performed by using SPSS software 11.0. Results: 1.Plasma sICAM–1 levels were significantly increased in newly diagnosed NHL patients (mean value 274.5±158.5ng/ml, range 110.8~667.3ng/ml) compared with normal controls (mean value 116.5±55.2ng/ml, range15.99~232.60ng/ml, P<0.05). 2.No stastistical significance was found when plasma sICAM–1 levels were compared with age, gender, histological subgroups and original sites involved in NHL patients (P>0.05). NHL patients with advanced stage (III/IV), B symptoms and bone marrow infiltration had higher plasma levels of sICAM–1 than the remainders (mean value 324.0±55.6 ng/ml versus 185.4±55.6 ng/ml, 334.1±183.0ng/ml versus 218.7±113.0ng/ml, 356.6±201.9ng/ml versus 235.4±110.0ng/ml, respectively; P<0.05, in each comparison). Patients with more than 1 extranodal site of involvement showed a tendency towards higher sICAM–1 levels compared to those with 0 or 1 extranodal site of involvement (mean value 340.6 ±183.7ng/ml versus 213.1 ±105.4ng/ml, respectively; P<0.05). 3.Plasma sICAM–1 levels were similar among normal control group and complete remission group, normal control group and partial remission group, normal control group and relapse group, initial therapy group and relapse group, complete remission group and partial remission group, complete remission group and relapse group, partial remission group and relapse group (P >0.05, in each comparison). Significant difference were found between normal control group and initial therapy group, initial therapy group and complete remission group, initial therapy group and partial remission group ( 116.5 ±55.2ng/ml versus 274.5 ±158.5ng/ml, 274.5±158.5ng/ml versus 123.8±60.3ng/ml, 274.5±158.5ng /ml versus 166.4±63.4ng /ml, respectively; P <0.01,in each comparison). 4.Plasma sICAM–1 levels were significantly increased in NHL patients before treatment compared with in the complete remission phase, the partial remission phase and the remission phase (CR +PR) after treatment, and significant difference were found among the patients in remission phase and relapse (P <0.05), but plasma sICAM–1 levels were similar among the patients before therapy and when relapse (P>0.05). 5.The NHL patients who can achieve complete remission after 1~3 cycles of standard chemotherapy have significantly lower plasma sICAM–1 levels than the patients who can't do it, and plasma sICAM–1 levels of death group and relapse group after 8~9 cycles of standard chemotherapy were significantly increased than the remainders (P <0.01,in each comparison). 6.The patients with elevated plasma sICAM–1 levels (mean value >255 ng/ml) less frequently achieved complete remission than those with normal plasma sICAM–1 levels (33.3% versus 72%, respectively; P<0.05), however, the patients with elevated plasma sICAM–1 levels more frequently died and relapsed than those with normal plasma sICAM–1 levels (50% versus 8%, 77.8% versus 24%, respectively; P<0.01, in each comparison). 7.The patients with high serum lactate dehydrogenase levels(LDH), high beta2-microglobulin levels and the...
|
PDF Full Text Request